ArticleEcancermedicalscience2025
High body mass index increases the risk for prostate cancer and high Gleason score in northern Tanzania: data from prostate cancer screening.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prevalence of Benign Prostatic Hyperplasia and Prostate Cancer Among Men Presenting with Lower Urinary Tract Symptoms at a Tertiary Referral Hospital in Dar es Salaam, Tanzania: A Retrospective Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Green tea catechins and prostate cancer: mechanisms, clinical evidence, and safety: a narrative review.BMC cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The association between body mass index (BMI) and prostate cancer (Pca) remains a controversial subject. Despite Pca being common in Tanzania, there is a scarcity of data on the role of BMI on Pca risk. This study aimed to assess the association between Pca and BMI among African men in Tanzania. Methods: This analysis included Tanzanian men aged ≥40 years who underwent prostate biopsy for the elevated prostate-specific antigen of >4 ng/mL during community-based Pca screening. Gleason scores of all Pca cases were determined by an experienced pathologist. BMI was calculated by dividing weight in kilograms by height in metre square. Participants were categorised into four BMI categories as follows: underweight (<18.5 kg/m Results: A total of 572 men underwent prostate biopsy after being found to have an elevated prostate-specific antigen of >4 ng/mL during screening. Of these, normal BMI accounted for 233 (40.7%), while overweight and obesity accounted for 153 (26.7%) and 141 (24.7%), respectively. In multivariate analysis, overweight men had significantly higher odds of being diagnosed with Pca (OR 6.95, 95% CI; 3.43-14.06) as compared to their normal-weight counterparts. The strength of the association became stronger among obese participants (OR 23.65, 95%CI; 11.45-48.87). Similarly, there was a significant increase in the odds of being diagnosed with high Gleason score Pca among obese men (OR 3.63, 95%CI; 1.52-8.70). Conclusion: Tanzanian men with elevated prostate-specific antigen and a high BMI have a significant risk of being diagnosed with Pca, mostly with a high Gleason score. Normal BMI maintenance might help in reducing the risk of developing Pca.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.